For two decades, the national narrative around menopausal hormone replacement therapy (HRT) has been shaped more by fear than by clinical nuance. When the FDA added “black box” warnings to estrogen- and progesterone-containing therapies in the early 2000s, the signal to the public was unmistakable: HRT was dangerous. The consequences were swift and severe. Prescriptions plummeted. Women dealing with debilitating menopausal symptoms backed away. And clinicians lost an opportunity to meaningfully integrate HRT into midlife women’s health.
How One Study Sparked a National Misstep
The decision was largely driven by the Women’s Health Initiative (WHI), a groundbreaking but imperfect study examining older post-menopausal women—many years past natural menopause—and their response to combined estrogen/progestin therapy. Findings suggested increased risks of breast cancer, heart disease, and stroke. What regulators failed to do was contextualize the results: age of initiation, time since menopause, type of hormone, route of delivery, and individualized risk profiles all matter. Instead, findings in a narrow sub-population became blanket guidance for everywoman.
The result was one of the most consequential oversimplifications in modern women’s health. As a result, half the population was effectively shut out from a therapy that, when appropriately prescribed, can yield substantial benefits.
The Consequences: Fear, Silence, and Stalled Innovation
The black box warnings reframed HRT as a high-risk intervention rather than a legitimate, evidence-based option for symptom relief, bone health, mood stabilization, cardiovascular support, and overall quality of life. According to an interview with FDA Commissioner Marty Makary, the labeling created a “fear machine” that prevented millions from receiving care they may have needed. Clinicians became risk-averse. Women stopped asking questions. And midlife care—already underdeveloped—stagnated further.
From a population-health standpoint, regulatory overreach delayed meaningful conversations around prevention, long-term wellness, and proactive midlife care strategies for women.
The Science Evolves—and So Does the Guidance
Over the past decade, the scientific community has revisited the data with a more critical lens. New evidence shows that initiating HRT within 10 years of menopause—or before age 60—is associated with lower all-cause mortality and fewer adverse outcomes than initiating later. In November 2025, the FDA and HHS issued updated guidance recommending the removal of black box warnings from most systemic estrogen/progestogen therapies—acknowledging that the original labeling overstated generalized risk. Warnings for endometrial cancer remain for estrogen-only therapy in women with a uterus, underscoring the importance of individualized care.
A Broader Pattern: Women’s Health Continues to Be Undervalued
The HRT episode is not an isolated failure; it fits a broader pattern in American medicine where women’s health is routinely marginalized. Consider:
- Surgical reimbursement for female urologic procedures lags considerably behind male analogs—yet are more complex.
- Ovarian cancer detection remains dismal, with nearly 80% diagnosed at Stage 4, while routine PSA screening for men—despite similar limitations—remains standard.
My opinion: “Big pharma doesn’t profit meaningfully from HRT,” which may partly explain the lack of urgency in correcting the record, the scrutiny of compounding pharmacies, and the professional backlash against physicians who offered individualized, evidence-based HRT care. This deserves investigation if we hope to rebuild trust among women who have repeatedly been failed by the system.
The Human Cost—and the Legacy of a Pioneer
Few understood this issue better than the late Dr. Joel Hargrove, a Vanderbilt-trained pharmacist and OB/GYN and an early champion of bioidentical hormones. Two decades ago, women traveled from across four states to his Columbia, Tennessee practice for care when mainstream medicine offered little more than dismissal. His approach was methodical, safety-as-first principle, and grounded in physiology. He recognized the dangers of unnecessary hormone exposure in younger women and the importance of restoring declining hormones in older women.
He was ridiculed for what we now understand to be right. It is a shame he did not live to see his work vindicated.
Where We Go from Here
The reversal of the FDA’s black box guidance is a step toward restoring scientific integrity—but it is not enough. We must understand how this misinformation persisted for 20 years, how millions suffered unnecessarily, and why women must continue to be their own advocates in a system that often deprioritizes their needs.
As Dr. Hargrove once told me, “Women have asked for everything—except this. And they don’t even know to ask.”
It’s time we make sure they know.